drugset
drugset / Trial / NCT07088263

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

NCT07088263 ↗

Phase 3 Recruiting 192 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.

Timeline

Start
2025-09-15
Primary completion
2027-07-24
Completion
2028-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Epothilone D Small molecule 30 mg/m2 Intravenous
Subject Eribulin Small molecule 1.4 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Vinorelbine Small molecule 25 mg/m2 Intravenous
Subject Vinorelbine Small molecule 60 mg/m2 Intravenous
Subject Vinorelbine Small molecule 80 mg/m2 Intravenous

Indications

breast neoplasm